连续性肾脏替代治疗与间歇性血液透析治疗重症急性肾衰的比较研究

目的 对比分析在重症急性肾衰治疗上运用连续性肾脏替代治疗方法与间歇性血液透析治疗方法的临床效果.方法 选择自2010年1月-2012年3月在该院接受治疗的500例重症急性肾衰患者,分成实验组和对照组各250例,实验组患者选择连续性肾脏替代治疗[1],对照组患者选择间歇性血液透析治疗,经过一段时间的治疗后对比实验组和对照组患者治疗前后血清肌酐(Scr)、尿素氮(BUN)、内生肌酐(Ccr)的水平的变化；并对2组患者进行调查随访,比较1年后的存活率.结果 比较结果发现实验组患者在Scr、BUN、Ccr方面的改善明显好于对照组,2组比较差异具有统计学意义(P＜0.05)；同时随访调查显示实验组患者的1年存活率也显著优于对照组,分别为82.4％和52.5％,2组比较差异具有统计学意义(P＜0.05).结论 与间歇性血液透析治疗相比,连续性肾脏替代治疗具有临床效果好、患者存活率高等优点,临床意义十分重要.

Continuous renal replacement therapy and intermittent hemodialysis in the treatment of severe acute renal failure

Objective Comparative analysis in severe acute renal failure treated with continuous renal replacement therapy and intermittent hemodialysis treatment clinical effect. Methods From 2010 January ~2012 year in March in our hospital for treatment of 500 cases of severe acute renal failure patients, divided into experimental group and control group with 250 cases in each group, the patients in experimental group selection of continuous renal replacement therapy in[1],the control group patients choose to intermittent hemodialysis, after a period of time of treatment in contrast to the experimental group and the control group of patients before and after treatment, serum creatinine ( Scr ), blood urea nitrogen(BUN), creatinine(Ccr)levels of change; and the two groups of patients were followed up after 1 years ofinvestigation, comparison of survival rate. Results Comparison of results found that patients in the experimental group Scr, BUN, Ccr improvements were significantly better than the control group, two groups with significant difference ( P<0.05 ); at the same time follow-up survey in the experimental group, 1 years survival rate is significantly better than the control group, respectively 82.4% and 52.5%, the difference between the two groups was statistically significance of (P<0.05 ). Conclusion Compared with intermittent hemodialysis, continuous renal replacement therapy has good clinical effect, high survival rate of the patients, clinical significance is very important.